@article {Adams2020.04.15.20066407, author = {Emily Adams and Mark Ainsworth and Rekha Anand and Monique I Andersson and Kathryn Auckland and J Kenneth Baillie and Eleanor Barnes and Sally Beer and John I Bell and Tamsin Berry and Sagida Bibi and Miles Carroll and Senthil K Chinnakannan and Elizabeth Clutterbuck and Richard J Cornall and Derrick W Crook and Thushan de Silva and Wanwisa Dejnirattisai and Kate E Dingle and Christina Dold and Alexis Espinosa and David W Eyre and Helen Farmer and Maria Fernandez Mendoza and Dominique Georgiou and Sarah J Hoosdally and Alistair Hunter and Katie Jeffery and Paul Klenerman and Julian Knight and Clarice Knowles and Andrew J Kwok and Ullrich Leuschner and Robert Levin and Chang Liu and C{\'e}sar L{\'o}pez-Camacho and Jose Martinez and Philippa C Matthews and Hannah McGivern and Alexander J Mentzer and Jonathan Milton and Juthathip Mongkolsapaya and Shona C Moore and Marta S Oliveira and Fiona Pereira and Elena Perez and Timothy Peto and Rutger J Ploeg and Andrew Pollard and Tessa Prince and David J Roberts and Justine K Rudkin and Veronica Sanchez and Gavin R Screaton and Malcolm G Semple and Donal T Skelly and Jose Slon-Campos and Elliot Nathan Smith and Alberto Sobrinodiaz and Julie Staves and David I Stuart and Piyada Supasa and Tomas Surik and Hannah Thraves and Pat Tsang and Lance Turtle and A Sarah Walker and Beibei Wang and Charlotte Washington and Nicholas Watkins and James Whitehouse}, title = {Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel}, elocation-id = {2020.04.15.20066407}, year = {2020}, doi = {10.1101/2020.04.15.20066407}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives The COVID-19 pandemic caused \>1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.Design We tested plasma for COVID (SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices.Setting We performed laboratory work at the University of Oxford.Participants We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).Main outcome measures We recorded optical density results from ELISA experiments and positive/negative/invalid results from LFIA devices.Results ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85\%, 95\%CI 70-94\%), vs. 0/50 pre-pandemic controls (specificity 100\% [95\%CI 93-100\%]). IgG levels were detected in 31/31 COVID-positive individuals tested >=10 days after symptom onset (sensitivity 100\%, 95\%CI 89-100\%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70\% versus RT-PCR and 65-85\% versus ELISA, with specificity 95-100\% and 93-100\% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.Conclusions Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.Competing Interest StatementRC reports personal fees and other from MIROBIO Ltd, outside the submitted work. DWE reports personal fees from Gilead, outside the submitted work. SH reports grants from NIHR, during the conduct of the study. AJP reports grants from NIHR Oxford Biomedical Research Centre, outside the submitted work; and AJP is Chair of UK Dept. Health and Social Care{\textquoteright}s (DHSC) Joint Committee on Vaccination \& Immunisation (JCVI) and is a member of the WHO{\textquoteright}s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. MGS reports grants from National Institute of Health Research, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging \& Zoonotic Infections, University of Liverpool, during the conduct of the study; other from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. ASW reports grants from NIHR, during the conduct of the study. No other author has a conflict of interest to declare.Funding StatementThis study was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, the UK Government Department of Health and Social Care and and grants from NIHR [award CO-CIN-01] and the Medical Research Council [grant MC_PC_19059]. DC, TEAP and ASW are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (NIHR200915). Blood donor and QUOD samples were provided with support from NHS Blood and Transplant and the Medical Research Council UK. SKC is supported by Medical Research Council UK. TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). DWE is a Robertson Foundation Fellow and NIHR Oxford BRC Senior Research Fellow. PM is a Wellcome Trust Clinical Research Fellow (110110/Z/15/Z) and NIHR Oxford BRC Senior Research Fellow. AM, PK, SCM, TPr, MGS and LT are supported by NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU-EZI) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with the University of Oxford and Liverpool School of Tropical Medicine (award number NIHR200907). EB, PK, AJP and ASW are NIHR Senior Investigators. PK (WT109965/MA) and GRS (095541/A/11/Z) are Wellcome Trust Senior Investigators. JR is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B). The views expressed are the author(s) and are not necessarily those of the NHS, the NIHR, the UK Department of Health and Social Care, the MRC or PHE.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResults generated for all samples and relevant metadata is provided in Table S7.}, URL = {https://www.medrxiv.org/content/early/2020/05/07/2020.04.15.20066407}, eprint = {https://www.medrxiv.org/content/early/2020/05/07/2020.04.15.20066407.full.pdf}, journal = {medRxiv} }